Sleep-HD: Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis

Sponsor

University of Washington (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03534284

Collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)

126

Enrollment

Location

Arms

48.7

Anticipated Duration (Months)

2.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Insomnia is a common and distressing symptom for patients on hemodialysis (HD), and there is evidence for a much larger impact on the health of patients. Chronic insomnia is disrupted sleep that occurs at least three nights per week and lasts at least three months.

The SLEEP-HD study is a randomized open-label clinical trial to compare two types of treatment for insomnia in participants who have end-stage renal disease on HD, and who have been diagnosed with chronic insomnia. The two types of treatment involved in the study are Cognitive Behavioral Therapy for Insomnia (CBT-I) or treatment with a drug (trazodone vs placebo).

126 participants will be enrolled who are undergoing HD in two study locations (Seattle, Washington and Albuquerque, New Mexico).

Condition or Disease	Intervention/Treatment	Phase
Insomnia End Stage Renal Disease	Behavioral: Cognitive Behavioral Therapy for Insomnia Drug: Trazodone Drug: Placebo	Phase 3

Detailed Description

Most HD patients have significant impairments in quality of life, largely from the high frequency of disabling symptoms. Insomnia is one of the most frequently reported symptoms and studies of HD patients and/or other populations suggest that it is a significant contributor to other common symptoms and poor health outcomes. There are unique contributors to chronic insomnia in HD patients and these include the biologic effects of residual uremia after partial correction as is achieved with current dialysis technology, maladaptation to treatment schedules, and patients' napping during treatments.

There is a compelling need to identify effective treatments for insomnia in HD patients and the interventions being studied in this clinical trial, telehealth cognitive behavioral therapy for insomnia (CBT-I) and trazodone, have a strong scientific premise. If telehealth (web-based) CBT-I is effective for insomnia in HD patients, it will make a treatment that is presently inaccessible available to patients. Trazodone is widely used but the data on efficacy for insomnia are limited; no such data exist for HD patients.

Study Design

Study Type:

Interventional

Actual Enrollment :

126 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

SLEEP-HD is a parallel group randomized controlled trial wherein 125 HD patients with chronic insomnia, treated in community-based dialysis facilities in Seattle and Albuquerque, will be randomized 1:1:1 over 31 months to 6-week treatment with telehealth CBT-I, trazodone, or medication placebo.SLEEP-HD is a parallel group randomized controlled trial wherein 125 HD patients with chronic insomnia, treated in community-based dialysis facilities in Seattle and Albuquerque, will be randomized 1:1:1 over 31 months to 6-week treatment with telehealth CBT-I, trazodone, or medication placebo.

Masking:

Triple (Participant, Care Provider, Investigator)

Masking Description:

The investigator, the participant, and the care provider will be blinded to the drug assignment (trazodone vs. placebo) for those subjects randomized into the medication intervention arm.

Primary Purpose:

Treatment

Official Title:

Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD)

Actual Study Start Date :

Sep 19, 2018

Anticipated Primary Completion Date :

Jun 6, 2022

Anticipated Study Completion Date :

Oct 10, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: CBT-I Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.	Behavioral: Cognitive Behavioral Therapy for Insomnia Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform. Other Names: CBT-I
Active Comparator: Medication- Trazodone Trazodone (50-100 mg):	Drug: Trazodone trazodone tablet Other Names: Desyrel
Placebo Comparator: Medication- Placebo Placebo (for trazodone)	Drug: Placebo Inactive pill manufactured to mimic trazodone tablets. Other Names: Placebo (for trazodone)

Arm

Intervention/Treatment

Active Comparator: CBT-I

Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.

Behavioral: Cognitive Behavioral Therapy for Insomnia

Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.

Other Names:

CBT-I

Active Comparator: Medication- Trazodone

Trazodone (50-100 mg):

Drug: Trazodone

trazodone tablet

Other Names:

Desyrel

Placebo Comparator: Medication- Placebo

Placebo (for trazodone)

Drug: Placebo

Inactive pill manufactured to mimic trazodone tablets.

Other Names:

Placebo (for trazodone)

Outcome Measures

Primary Outcome Measures

Insomnia Severity Index (ISI) Short-term [Week 7]
summary score obtained from the ISI, measuring insomnia, range from 0 to 28. Higher score indicates greater insomnia, at Week 7 describing the short-term effect of the intervention
Insomnia Severity Index (ISI) Long-term [Week 25]
summary score obtained from the ISI, measuring insomnia, range from 0 to 28. Higher score indicates greater insomnia, at Week 25 describing the long-term effect of the intervention

Secondary Outcome Measures

Patient-reported Outcomes (PRO) - Pittsburgh Sleep Quality Index - Short-term [Week 7]
Score from Pittsburgh Sleep Quality Index, measuring sleep quality, range 0 to 21. Higher scores indicates worse sleep quality: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - Pittsburgh Sleep Quality Index - Long-term [Week 25]
Score from Pittsburgh Sleep Quality Index, measuring sleep quality, range 0 to 21. Higher scores indicates worse sleep quality: at Week 25 describing the long-term effect of the intervention
Patient-reported Outcomes (PRO) - Epworth Sleepiness Scale - Short-term [Week 7]
Score from Epworth Sleepiness Scale, measuring sleepiness, range 0 to 24. Higher scores indicates greater sleepiness: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - Epworth Sleepiness Scale - Long-term [Week 25]
Score from Epworth Sleepiness Scale, measuring sleepiness, range 0 to 24. Higher scores indicates greater sleepiness: at Week 25 describing the long-term effect of the intervention
Patient-reported Outcomes (PRO) - FACIT Fatigue Scale- Short-term [Week 7]
Score from FACIT Fatigue Scale, measuring fatigue, range 0 to 52. Higher scores indicates greater fatigue: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - FACIT Fatigue Scale- Long-term [Week 25]
Score from FACIT Fatigue Scale, measuring fatigue, range 0 to 52. Higher scores indicates greater fatigue: at Week 25 describing the long-term effect of the intervention
Patient-reported Outcomes (PRO) - Two-Item Graded Chronic Pain scale - Short-term [Week 7]
Score from Two-Item Graded Chronic Pain scale, measuring pain, range 0 to 10. Higher scores indicates greater pain: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - Two-Item Graded Chronic Pain scale - Long-term [Week 25]
Score from Two-Item Graded Chronic Pain scale, measuring pain, range 0 to 10. Higher scores indicates greater pain: at Week 25 describing the long-term effect of the intervention
Patient-reported Outcomes (PRO) - Patient Health Questionnaire 9 - Short-term [Week 7]
Score from Patient Health Questionnaire 9, measuring depression, range 0 to 27. Higher scores indicates greater depression: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - Patient Health Questionnaire 9 - Long-term [Week 25]
Score from Patient Health Questionnaire 9, measuring depression, range 0 to 27. Higher scores indicates greater depression: at Week 25 describing the long-term effect of the intervention
Patient-reported Outcomes (PRO) - Generalized Anxiety Disorder 7 Scale - Short-term [Week 7]
Score from Generalized Anxiety Disorder 7 Scale, measuring anxiety, range 0 to 21. Higher scores indicates greater anxiety: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - Generalized Anxiety Disorder 7 Scale - Long-term [Week 25]
Score from Generalized Anxiety Disorder 7 Scale, measuring anxiety, range 0 to 21. Higher scores indicates greater anxiety: at Week 25 describing the long-term effect of the intervention
Patient-reported Outcomes (PRO) - Quality of Life Short Form 12 scale - Short-term [Week 7]
Score from Quality of Life Short Form 12 scale, measuring quality of life, range 0 to 100. Higher scores indicates better quality of life: at Week 7 describing the short-term effect of the intervention
Patient-reported Outcomes (PRO) - Quality of Life Short Form 12 scale - Long-term [Week 25]
Score from Quality of Life Short Form 12 scale, measuring quality of life, range 0 to 100. Higher scores indicates better quality of life: at Week 25 describing the long-term effect of the intervention
Cumulative Weekly use of Sedatives/Hypnotics - Short-term [Week 7]
This will be defined, as the number of days that the patient took a drug to help sleep, range from 0 to 7: at Week 7 describing the short-term effect of the intervention
Cumulative Weekly use of Sedatives/Hypnotics - Long-term [Week 25]
This will be defined, as the number of days that the patient took a drug to help sleep, range from 0 to 7: at Week 25 describing the long-term effect of the intervention
Objective Measure of Sleep - Short-term [Week 6]
Actigraphy measurement of average nighttime sleep efficiency (percent time asleep of time in bed): at Week 6 describing the short-term effect of the intervention
Objective Measure of Sleep - Long-term [Week 25]
Actigraphy measurement of average nighttime sleep efficiency (percent time asleep of time in bed): at Week 25 describing the long-term effect of the intervention

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Undergoing thrice-weekly maintenance hemodialysis for ≥ 3 months
Able to speak English
ISI score ≥ 10 at pre-screening with sleep disturbances for ≥ 3 nights per week for ≥ 3 months

Exclusion Criteria:

Severe cognitive impairment on Mini-COG cognitive test (score < 3)
Severe depression assessed by Patient Health Questionnaire (PHQ)-2 and if appropriate, PHQ-9
Suicidal Ideation
Alcohol abuse on CAGE alcohol assessment questionnaire (score ≥ 2) or substance abuse on Drug Abuse Screening Test (DAST)-10 questionnaire (score > 5)
Severe restless leg syndrome
Treatment with trazodone in the past one month
Known allergy to trazodone (self-report or by chart review)
Current treatment with monoamine oxidase inhibitors or in the preceding 14 days
Current treatment with linezolid (self-report or by chart review)
Current treatment with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (ziprasidone, chlorpromazine, thioridazine), and quinolone antibiotics
Pregnancy, or lactation, or women of childbearing potential not willing to use adequate birth control
Life Expectancy < 3 months
Expected to receive a kidney transplant or transition to home dialysis (peritoneal dialysis or home hemodialysis) within 6 months
Any other condition that, in the opinion of the investigator, should preclude patient participation in the clinical trial